Report scope. This 2026 Drug Asset Due Diligence Report evaluates 212Pb-AR-RMX as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: HOLD / OPTION
212Pb-AR-RMX is a Peptide Conjugate Radionuclide associated with SSTR and a global highest development stage of Phase 2. The lead disclosed indication is Somatostatin Receptor-Positive Neuroendocrine Tumor. The current evidence supports a HOLD / OPTION posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: 212Pb-AR-RMX
- Target: SSTR
- Lead indication: Somatostatin Receptor-Positive Neuroendocrine Tumor
- Highest phase: Phase 2
- Matched trials: 0
- Matched result records: 9
- Matched asset deals: 1
Use PatSnap Life Sciences MCP servers to validate the 212Pb-AR-RMX diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For 212Pb-AR-RMX, the MCP profile identifies SSTR as the primary target context and Somatostatin Receptor-Positive Neuroendocrine Tumor as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the 212Pb-AR-RMX diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| No asset-specific registered study was returned by the MCP query. Confirm sponsor records and registry synonyms before a licensing decision. | ||||
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the 212Pb-AR-RMX diligence evidence.
3. Clinical readouts: what is known
1032O - Efficacy and safety of targeted alpha therapy 212Pb-DOTAMTATE in patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) previously treated with peptide receptor radionuclide therapy (PRRT): Results of a phase II study
Study: NCT05153772 (ALPHAMEDIX 02, ESMO2025). Phase: Phase 2. Enrollment: 26. Published: 2025-10-17.
TEAE(≥Grade 3) = 34.6 %
1034MO - Long-term follow-up of peptide receptor radionuclide therapy (PRRT)-naïve patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with targeted alpha therapy 212Pb-DOTAMTATE in the phase II ALPHAMEDIX 02 trial
Study: NCT05153772 (ALPHAMEDIX 02, ESMO2025). Phase: Phase 2. Enrollment: 1034. Published: 2025-10-17.
ORR = 57.1 % ( 39.4 - 73.7)
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Study: NCT05153772 (ALPHAMEDIX 02, Company_Website). Phase: Phase 2. Enrollment: Not disclosed. Published: 2025-10-08.
ORR(RECIST 1.1) = AlphaMedix met all primary efficacy endpoints and showed clinically meaningful overall response rates. Met | ORR(RECIST 1.1) = AlphaMedix met all primary efficacy endpoints and showed clinically meaningful overall response rates. Met
Safety, tolerability and efficacy of212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.
Study: NCT05153772 (ALPHAMEDIX 02, ASCO2024). Phase: Phase 2. Enrollment: Not disclosed. Published: 2024-05-24.
ORR = 47.2 % (95%CI, 32.0 - 63.0) | ORR = 18 % (95%CI, 10 - 25)
Targeted Alpha-Emitter Therapy with 212Pb-DOTAMTATE in Neuroendocrine Tumor Subjects who Progressed Following Prior PRRT
Study: 212Pb-DOTAMTATE (SNMMI2022). Phase: Not Applicable. Enrollment: 11. Published: 2022-08-08.
ORR = 30 %
Targeted alpha-emitter therapy with 212Pb-DOTAMTATE in neuroendocrine tumor subjects who progressed following prior 177Lu/90Y-PRRT.
Study: NCT03466216 (ASCO2022). Phase: Phase 1. Enrollment: 10. Published: 2022-06-02.
SAE = 3 Pts
Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients.
Study: NCT03466216 (ASCO 12021 | ASCO 22021). Phase: Phase 1. Enrollment: 20. Published: 2021-05-20.
SAE = 0 Pts
First-in-human dose escalation of AlphaMedix for targetedalpha-emitter therapy of neuroendocrine tumors
Study: AlphaMedix (EANM2020). Phase: Not Applicable. Enrollment: 16. Published: 2020-09-18.
Adverse Event: alopecia = 7/16 (43%) | Adverse Event: alopecia = 7/16 (43%)
Abstract CT159: First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of neuroendocrine tumors
Study: AACR2020. Phase: Not Applicable. Enrollment: 13. Published: 2020-08-15.
Adverse Event: investigational drug-related hematological and renal toxicity = No clinically significant investigational drug-related hematological and renal toxicity was noted.
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the 212Pb-AR-RMX diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark 212Pb-AR-RMX against approved therapies and clinical competitors in Somatostatin Receptor-Positive Neuroendocrine Tumor, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the 212Pb-AR-RMX diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2024-09-12 | Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers | Active | License | Disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the 212Pb-AR-RMX diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
HOLD / OPTION
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
